---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-072980"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2026-06-11T20:43:01+00:00"
generated_at: "2026-06-11T20:44:25.785972+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Humacyte prices $50M public offering of 47.6M shares at $1.05 per share

## Summary
- Sold 47,619,048 shares at $1.05/share; gross proceeds ~$50M.
- Net proceeds expected ~$46.8M (~$53.85M if underwriters exercise 30-day over-allotment of 7,142,857 shares).
- Proceeds to fund Symvess commercialization, BLA supplement for hemodialysis, pipeline development, and working capital.
- Offering expected to close June 12, 2026; joint book-runners: Barclays, BTIG, Titan Partners.
- 30-day underwriter option for additional 15% of shares at same price.

## SEC filing metadata
- accession: 0001104659-26-072980
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2026-06-11T20:43:01+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000110465926072980/0001104659-26-072980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000110465926072980/tm2617224d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-072980
- JSON: https://secwatch.observer/filing/0001104659-26-072980.json
- Plain text: https://secwatch.observer/filing/0001104659-26-072980.txt

## Key facts
- Material Agreements
  Humacyte, Inc. entered into Underwriting Agreement with Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC, a division of American Capital Partners, LLC, as representatives of the several underwriters named therein valued at approximately $46.80 million (effective 2026-06-10).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC, a division of American Capital Partners, LLC, as representatives of the several underwriters named therein
  - Value: approximately $46.80 million
  - Effective: 2026-06-10
  source text: On June 10 , 2026, Humacyte, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC, a division of American Capital Partners, LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”), pursuant to which the Company agreed to issue and sell 47,619,048 shares of the Company’s common stock, $0.0001 par value per share, at a price to the public of $1.05 per share (the “Firm Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465926072980/0001104659-26-072980-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.